BioSpace News Archive

Business

Curis Provides First Quarter 2024 Business Update

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the first quarter ended March 31, 2024.

May 7, 2024
·
11 min read
Business

Caring Cross and ImmunoAdoptive Cell Therapy (ImmunoACT) Announce Agreement to Commercialize TriCAR-T Cell Immunotherapy for Leukemia and Lymphoma

Caring Cross and ImmunoAdoptive Cell Therapy (ImmunoACT) announced an agreement to develop and commercialize a multi-targeted chimeric antigen receptor T-cell immunotherapy for leukemia and lymphoma.

May 7, 2024
·
4 min read
Pharm Country

Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference

Rallybio Corporation announced that Steve Uden, M.D., Chief Executive Officer of Rallybio, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024 at 11:30 a.m. ET in New York, NY.

May 7, 2024
·
1 min read
Pharm Country

Ultrasound Neuromodulation Shows Promise to Treat Pulmonary Hypertension, Feinstein Institutes Research

Bioelectronic medicine scientists at The Feinstein Institutes for Medical Research used noninvasive, splenic focused ultrasound stimulation (sFUS) and found they can reduce inflammation and improve symptoms of pulmonary arterial hypertension (PAH).

May 7, 2024
·
6 min read
BioCapital

US Medical Innovations Secures FDA Clearance for Canady Helios Cold Plasma™ Ablation System

US Medical Innovations, LLC (USMI) announced today it has received FDA 510k Clearance (K240297) for the Canady Helios Cold Plasma™ (CHCP) Ablation System for the ablation of soft tissue during surgery.

May 7, 2024
·
4 min read
Drug Development

Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting

Annexon, Inc. (Nasdaq: ANNX) today presented new analyses of ANX007 from the Phase 2 ARCHER trial in geographic atrophy (GA), and new preclinical data on the role of C1q in the pathogenic elimination of photoreceptor synapses and their protection with C1q blockade in GA.

May 7, 2024
·
11 min read
Business

MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2024

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today provided a business update and highlights its key milestones for 2024.

May 7, 2024
·
9 min read
Phizzle Introduces First Data Transformation Engine for BioPharma/GMP Use; Makes it Possible to Harmonize Data into any LIMs from any Instrument

At the BioTalk Conference near Boston, Phizzle, Inc., today introduced the industry’s first Data Transformation Engine, a software innovation that makes it possible to harmonize data from different lab instruments into any standard LIMs -- closing a major gap in data integrity for BioPharma manufacturers.

May 7, 2024
·
1 min read
Antipsychotic Drugs Market Size to Capture USD 37.40 Billion by 2032

The antipsychotic drugs market was valued at USD 18.04 billion in 2023 and is expected to reach around USD 37.40 billion by 2032, rising at a CAGR of 7.8% from 2024 to 2032.

May 7, 2024
·
9 min read
Business

TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024

TRACON Pharmaceuticals, Inc. announced that it will report its first quarter 2024 financial and operating results after the close of U.S. financial markets on Tuesday, May 14, 2024.

May 7, 2024
·
2 min read